China Meheco(SH:600056) Ge Long Hui A P P·2025-08-13 08:00Core Viewpoint - China Medical (600056.SH) announced that its wholly-owned subsidiary Tianfang Pharmaceutical Co., Ltd. received approval from the National Medical Products Administration for the marketing application of Fumaric Acid Vonoprazan, which is primarily used for treating gastroesophageal reflux disease and in combination with appropriate antibiotics to eradicate Helicobacter pylori [1] Group 1 - The drug Fumaric Acid Vonoprazan has been approved for marketing, indicating a significant development for the company [1] - The approval is expected to enhance the company's product portfolio in the gastrointestinal treatment sector [1] - The drug's indication for use in combination with antibiotics highlights its potential in addressing common gastrointestinal infections [1]